HCPCS Q4079 is referenced in 2 tracked payer policy changes from New Jersey Medicaid and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q4079 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
New Jersey Medicaid has clarified reimbursement rules for physician and outpatient-administered drugs, including LARC devices. Providers must now bill their actual drug acquisition cost as the submitted charge, and use modifier 'U8' when billing 340B drugs or LARC devices.
Aetna's Clinical Policy Bulletin 0020 on injectable medications was last reviewed March 5, 2026 and is scheduled for its next review January 14, 2027, but the page does not list what changed. It covers injectables when no appropriate oral alternative exists, excludes experimental drugs and performance-enhancing steroids, and notes that contraceptive injectables, infertility injectables and travel immunizations are excluded under some benefit plans.
Watch Q4079
Get one email when a payer policy names Q4079, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.